Influvac Tetra

B/Phuket/3073/2013‑Like Virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredients in Influvac Tetra, are vaccine antigens presented as a sterile suspension for intramuscular or subcutaneous injection. They are used to stimulate immunity against seasonal influenza strains in individuals aged six months and older.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Tetra is a quadrivalent influenza vaccine indicated for prevention of influenza infection.

Seasonal influenza: induces protective immunity against the four included influenza virus strains High‑risk populations (elderly, chronic disease): lowers risk of severe influenza complications Pregnant women (second/third trimester): helps prevent influenza‑related morbidity

Like other injectable vaccines, Influvac Tetra may be associated with local and systemic reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site - Redness or swelling: localized erythema or edema - Low‑grade fever: transient temperature rise - Headache or muscle aches: mild systemic symptoms

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention - Guillain‑Barré syndrome: rare neurological disorder reported post‑vaccination - Seizures: infrequent febrile seizures in young children

Before administering Influvac Tetra, consider the following precautions.

Allergy assessment: avoid if known severe allergy to any vaccine component Previous vaccine reaction: evaluate prior severe reactions before administration Acute illness: defer vaccination until recovery from moderate or severe febrile illness Pregnancy: discuss risk‑benefit with healthcare provider Immunocompromised status: may have reduced response, monitor effectiveness Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake

Influvac Tetra may interact with other medical products; review the following.

Major Interactions (Avoid): - Live vaccines: avoid co‑administration within 4 weeks due to potential interference - Immunoglobulin therapy: may reduce vaccine efficacy if given within 2 weeks

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): may blunt antibody response if taken prophylactically - High‑dose corticosteroids: may diminish immune response - Other inactivated vaccines: can be administered concomitantly at different sites